Compare SEVN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEVN | NNNN |
|---|---|---|
| Founded | 1986 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.9M | 154.1M |
| IPO Year | 2008 | 2023 |
| Metric | SEVN | NNNN |
|---|---|---|
| Price | $6.70 | $3.81 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.70 | N/A |
| AVG Volume (30 Days) | ★ 175.7K | 47.8K |
| Earning Date | 10-27-2026 | 11-24-2026 |
| Dividend Yield | ★ 16.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $15.13 | N/A |
| Revenue Next Year | $16.21 | N/A |
| P/E Ratio | ★ $13.12 | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.98 | $3.09 |
| 52 Week High | $9.81 | $44.73 |
| Indicator | SEVN | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 45.71 |
| Support Level | $5.98 | $3.21 |
| Resistance Level | $7.05 | $6.95 |
| Average True Range (ATR) | 0.19 | 0.38 |
| MACD | 0.06 | 0.16 |
| Stochastic Oscillator | 64.21 | 59.36 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).